Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

This study is for adults aged 18 and over who have multiple myeloma that has either come back or isn't responding to previous treatments.

To be considered, your overall health should be reasonably good, and doctors need to be able to measure your cancer to see how well treatments are working. You must also have received at least two past treatments for multiple myeloma, including specific types of medication. However, if you're in the US or Puerto Rico, you only need to have had one past treatment that included these specific types of medication. You also need to be a suitable candidate for one of the standard treatments used in this study.

You cannot join if you have certain other serious health problems, a history of drug or alcohol misuse recently, or if your multiple myeloma has spread to your brain or spinal cord. If you've had a specific type of treatment called BCMA-targeted therapy, you also won't be able to join this study.

If you decide to take part in this study, you'll be involved for about three and a half years. During this time, you will have regular visits to your hospital or clinic. At these visits, you will receive your assigned study medication – either etentamig or a standard treatment – as a drip into a vein. This will happen in 28-day cycles.

Throughout the study, the medical team will carry out regular checks to see how you're responding. This will involve medical assessments, blood tests, carefully watching for any side effects, and asking you to complete questionnaires about how you're feeling. There might be more hospital visits and tests involved in this study compared to your usual care, but the team will guide you through everything.